City page
Schlieren biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Tools (2) and Therapeutics (1). Most visible records: InSphero AG, Memo Therapeutics AG, and Biognosys.
Which standards and public evidence are already visible?
Not yet available.. Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Schlieren.
By category
Schlieren by category
Jump into a category page filtered to this country only.
Full list
Schlieren biotech and pharma directory
3 city records currently match the active filter.
Current review cycle
InSphero AG
SchlierenSwitzerlandTools
Schlieren ETH Zurich spin-off pioneering industrial-grade 3D cell-based assays and scaffold-free organ-on-a-chip technology for drug safety and efficacy testing, with subsidiaries in the US and Germany.
- Lead
- Jan LichtenbergChief Executive Officer and Co-Founder
- Scale
- Industrial tools and assay manufacturing
Current review cycle
Memo Therapeutics AG
SchlierenSwitzerlandTherapeutics
Schlieren antibody-discovery biotech built on the proprietary DROPZYLLA microfluidic single-cell platform, with a Phase II lead program (potravitug) for BK polyomavirus in kidney transplantation and a 2026 CSL collaboration worth up to 328 million USD.
- Lead
- Erik van den BergChief Executive Officer
- Scale
- Late-stage clinical antibody development
Current review cycle
Biognosys
SchlierenSwitzerlandTools
Schlieren proteomics company providing discovery, translational, and clinical proteomics services and software from a strong Swiss life-science tools platform.
- Lead
- Oliver RinnerChief Executive Officer and Co-Founder
- Scale
- Global proteomics platform
Related briefs
Briefs that mention Schlieren
Swiss Biotech & Pharma Landscape 2026: Basel, Lausanne, Zurich
A practical map of the Swiss biotech and pharma landscape in 2026 — 36 operators anchored by Roche and Novartis in Basel, peptide and oligonucleotide API at Bachem, large-scale biologics at Lonza, and Lemanic + Zurich innovation clusters.
Open briefEuropean Antibody & Biosimilar Therapeutics 2026: mAbs, ADCs, Biosimilars
A practical map of the European antibody + antibody-drug-conjugate + biosimilar therapeutics sector in 2026 — Genmab, ADC Therapeutics, Adcendo, Affimed, Tubulis, Heidelberg Pharma, Sandoz, Mabion, plus a Swedish + Swiss + Polish antibody innovator belt.
Open briefEuropean Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK
Where to run European drug discovery services in 2026 — Evotec, Selvita, Charles River Finland, Gubra, Admescope, plus a Swiss + Polish + Nordic tool + platform layer for medicinal chemistry, DMPK, ADMET, and translational research.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.